Week in Review: Ping An Announces $1 Billion Fin-Tech/Healthcare VC Fund

Ping An Insurance launched a $1 billion international VC fund that will invest in fin-tech and healthcare startups; WuXi NextCODE, the contract genomics arm of the WuXi Group, closed a $75 million Series B financing; Epic Sciences, a San Diego IVD maker, completed a $40 million Series D round led by Hong Kong's Hermed Capital; China's Maccura Biotech formed a JV with Qiagen to commercialize Qiagen's GeneReader NGS system in China; Uni-Bio Science launched Bokangtai, its oral treatment for Type 2 diabetes, in Fujian province; Venus Medtech of Hangzhou received CFDA registration to market its transcatheter aortic valve system; Impact Therapeutics of Nanjing announced its IND for a PARP inhibitor was approved by the CFDA; Sirnaomics, a US-China RNAi company, received China approval of its Class 1.1 IND application for a hypertrophic scar treatment; Beijing's Yisheng Biopharma dosed the first patient in a Phase I trial of its immuno-oncology candidate aimed at solid tumor cancers; Sorrento Therapeutics, a San Diego-Nanjing company, completed construction of a manufacturing plant in Suzhou for antibody drug conjugates; and CARsgen opened its new manufacturing facility in Shanghai for CAR-T therapies. More details.... Stock Symbols: (HK: 2318; SHA: 601318) (SHZ: 300463) (NSDQ: QGEN) (HK: 690) (NSDQ: SRNE) Share this with colleagues: // //